Kyverna Therapeutics (KYTX)
Develops miv-cel, an autologous CD19 CAR-T candidate for B-cell-driven autoimmune diseases.
Something off on this page? Send us feedback.
Develops miv-cel (KYV-101), an autologous CD19-targeting CAR-T candidate for B-cell-driven autoimmune diseases. The clinical-stage company focuses first on neuroimmunology and is advancing studies in stiff person syndrome, generalized myasthenia gravis, multiple sclerosis, and rheumatoid arthritis.
Develops miv-cel (KYV-101), an autologous CD19-targeting CAR-T candidate for B-cell-driven autoimmune diseases. Initial neuroimmunology work centers on stiff person syndrome and generalized myasthenia gravis, while studies also cover multiple sclerosis and rheumatoid arthritis.
The program relies on a CAR construct licensed from the U.S. National Institutes of Health, an asset-origin choice that shaped the company's autoimmune focus. Founded in 2018, Kyverna operates from Emeryville, California, and adopted its current name in 2019. It is a clinical-stage business, so development progress and the conduct of its studies determine its operating frame.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 15, 2026 | H.C. Wainwright | Target | Target: $20 | Target: $25 |
| Dec 16, 2025 | Wells Fargo | Reiterate | Rating: —Target: — | Target: $33 |
| Dec 15, 2025 | UBS | Target | Target: — | Target: $32 |
| Dec 15, 2025 | Morgan Stanley | Target | Target: $25 | Target: $33 |
| Dec 4, 2025 | Morgan Stanley | Reiterate | Rating: —Target: — | Target: $25 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $199.4M · Total debt $33.0M · Total assets $219.8M · Shareholders' equity $165.5M
- Revenue
- $0
- Operating income
- −$39.6M
- Net income
- −$38.3M
No dividends on record.
| Institutions | ≈ 61.26% | 37.89M shares | |
|---|---|---|---|
| 128 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.98% | 1.23M shares | |
| 13 holders · as of May 29, 2026 | |||
| Strategic holders | 7.53% | 4.66M shares | |
| 2 holders · as of Feb 6, 2026 | |||
| Other | ≈ 29.23% | 18.07M shares | |
| remainder | |||
61.84M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gordonmd Global Investments LPInstitution | 6.86% | 4.24M | as of Jun 30, 2026 |
Gilead Sciences, Inc.Institution | 6.67% | 4.13M | as of Jun 30, 2026 |
Westlake BioPartners Fund I, L.P.1,2Strategic10 percent owner | 6.13% | 3.79M | filed Feb 6, 2026 |
BlackRock, Inc.Institution | 5.07% | 3.13M | as of Jun 30, 2026 |
Bain Capital Life Sciences Opportunities III, LPInstitution | 5.03% | 3.11M | filed Feb 17, 2026 |
- Westlake BioPartners Fund I, L.P.'s transaction reports restate only vehicles that traded; the 2026 ownership statement (3.79M) is used instead.
- Westlake BioPartners Fund I, L.P. reports a block also reported by another filer; it is counted once, under that filer.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P. | 10 percent owner | +133,333 | $7.50 |
| Dec 18, 2025 | Beth C. Seidenberg | director | +133,333 | $7.50 |
| Dec 15, 2025 | Karen Marie Walker | officer: Chief Technology Officer | −23,998 | $12.20 |
- Cabaletta Bio
Autologous CD19 CAR-T programs across overlapping autoimmune diseases
- Novartis (ADR)
Rapid-manufacturing CD19 CAR-T in lupus and myasthenia gravis
- Bristol-Myers Squibb
Autologous CD19 CAR-T in severe refractory autoimmune diseases
- AstraZeneca (ADR)
Dual CD19/BCMA CAR-T program for refractory lupus
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kyverna Therapeutics | $7.03 | −6.36% | $456.6M | — | — | — | — |
| Cabaletta Bio | $2.31 | −7.80% | $407.6M | — | — | — | — |
| Novartis (ADR) | $142.21 | +0.66% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Bristol-Myers Squibb | $61.76 | −0.79% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| AstraZeneca (ADR) | $164.51 | −2.30% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Median | 21.3 | 15.1 | 4.3 | +5.7% |